AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

1.935

-0.060-3.01%

Volume:3.23M

Turnover:6.31M

Market Cap:2.51B

PE:-30.32

High:2.040

Open:1.990

Low:1.925

Close:1.995

52wk High:3.310

52wk Low:1.880

Shares:1.30B

Float Shares:786.49M

Volume Ratio:1.20

T/O Rate:0.41%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.064

EPS(LYR):-0.064

ROE:-9.86%

ROA:-4.11%

PB:3.07

PE(LYR):-30.32

Loading ...

Overview Company News Filings

Mesoblast Ltd - Reports Qtrly Ryoncil Net Revenues of $30.3 Mln

THOMSON REUTERS

ASX Growth Companies With High Insider Ownership In April 2026

Simply Wall St.

Mesoblast files Form 3 as director Lynette Cobley reports beneficial ownership

Stock Track | Mesoblast Soars 5.12% Intraday on Patient Recruitment Milestone in Phase 3 Back Pain Trial

BUZZ-ASX-shares of Mesoblast rise after back-treatment drug hits patent target

Mesoblast hits recruitment target in Phase 3 chronic low back pain trial

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain

THOMSON REUTERS

Mesabi Trust (MSB) Q3 Net Margin Strengthens Bearish Dividend Coverage Narratives

Simply Wall St.

Mesoblast (ASX:MSB) Is Up 6.1% After FDA Clears Registrational DMD Trial for Ryoncil

Simply Wall St.

Mesoblast (ASX:MSB) Valuation Check As New CAR Technology License Targets Stronger Cell Therapy Pipeline

Simply Wall St.

Mesoblast Acquires Exclusive License to Chimeric Antigen Receptor Platform; Shares Up 7%

MT Newswires Live

Australian stocks edge higher as investors focus on US-Iran talks

BUZZ-Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech

BRIEF-Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products

Stock Track | Mesoblast Soars 5.22% Intraday on Acquisition of CAR-MSC Platform with Exclusive Mayo Clinic License

Mesoblast acquires CAR-MSC platform startup, secures exclusive Mayo Clinic license

Mesoblast Acquires Chimeric Antigen Receptor (Car) Platform Technology for Precision-Enhanced Cell Products

THOMSON REUTERS

Mesoblast Ltd-Acquires Car Platform for Precision-Enhanced Cell Products

THOMSON REUTERS

Mesoblast Ltd - Obtains Worldwide Exclusive Rights to Car-MSC Ip From Mayo Clinic

THOMSON REUTERS

Mesoblast Ltd - to Incorporate Engineered Cars to Enhance Product Specificity

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/MSB.AU/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":1.935,"timestamp":1791436320000,"preClose":1.995,"halted":0,"volume":3232575,"delay":0,"changeRate":-0.030075187969924838,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1296862776,"eps":-0.06381015616242272,"marketStatus":"Not Yet Opened","change":-0.06,"latestTime":"10-08 16:12:00 AEDT","open":1.99,"high":2.04,"low":1.925,"amount":6312384,"amplitude":0.057644,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.06381015616242272,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791500400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.995,"openAndCloseTimeList":[[1791414000000,1791435600000]],"volumeRatio":1.199847625635148,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":1.995,"auctionPrice":1.935,"auctionVolume":403083,"auction":3,"marketStatus":"盘后竞价","timestamp":1791436203501}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-4.11%","roe":"-9.86%","lyrEps":-0.06381,"volumeRatio":1.199847625635148,"shares":1296862776,"dividePrice":0,"high":2.04,"amplitude":0.057644,"preClose":1.995,"low":1.925,"week52Low":1.88,"pbRate":"3.07","psRate":"14.52","week52High":3.31,"institutionHeld":0,"latestPrice":1.935,"eps":-0.06381015616242272,"divideRate":0,"volume":3232575,"delay":0,"ttmEps":-0.06381015616242272,"open":1.99,"prevYearClose":2.72,"prevWeekClose":2.04,"prevMonthClose":2.11,"prevQuarterClose":2.11,"fiveDayClose":2.07,"twentyDayClose":2.17,"sixtyDayClose":2.77,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2631575532","title":"Mesoblast Ltd - Reports Qtrly Ryoncil Net Revenues of $30.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2631575532","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631575532?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:57","pubTimestamp":1777507051,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C20G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7508","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631520999","title":"ASX Growth Companies With High Insider Ownership In April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631520999","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631520999?lang=en_us&edition=fundamental","pubTime":"2026-04-30 03:08","pubTimestamp":1777489699,"startTime":"0","endTime":"0","summary":"As Australian shares enter their seventh consecutive day in the red, market sentiment has shifted into bearish territory amid concerns over rising inflation and potential interest rate hikes. In this challenging environment, growth companies with high insider ownership can be appealing as they often indicate strong confidence from those who know the business best.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/2054000-choice2-main-header/1585187245570","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2054000-choice2-main-header/1585187245570"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ipx/iperionx-shares/news/asx-growth-companies-with-high-insider-ownership-in-april-20-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ipx/iperionx-shares/news/asx-growth-companies-with-high-insider-ownership-in-april-20-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7084","FRS.AU","BK7094","TOR.AU","BK7067","ELS.AU","EIQ.AU","BK7023","BK7508","AV1.AU","AEM.AU","MAU.AU","MSB.AU","XKO.AU","BK7110","SPL.AU","AR1.AU","BK7016","BK7116","XAO.AU","SKS.AU","BK7017","BK7096","BK7095","BK7104","BK7501","XJO.AU","AYA.AU","IPX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631759459","title":"Mesoblast files Form 3 as director Lynette Cobley reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2631759459","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631759459?lang=en_us&edition=fundamental","pubTime":"2026-04-29 18:22","pubTimestamp":1777458121,"startTime":"0","endTime":"0","summary":"Mesoblast Form 3 shows director Lynette Elizabeth Cobley reporting 63,000 ordinary shares as of March 18, 2026.Filing also discloses 200,000 options exercisable at $1.72, expiring May 9, 2032.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL66nDbR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MSB.AU","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156659915","title":"Stock Track | Mesoblast Soars 5.12% Intraday on Patient Recruitment Milestone in Phase 3 Back Pain Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1156659915","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156659915?lang=en_us&edition=fundamental","pubTime":"2026-04-29 11:50","pubTimestamp":1777434632,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock surged 5.12% during intraday trading on Wednesday, following the company's announcement of a key development milestone for its chronic low back pain treatment.The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631455426","title":"BUZZ-ASX-shares of Mesoblast rise after back-treatment drug hits patent target","url":"https://stock-news.laohu8.com/highlight/detail?id=2631455426","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631455426?lang=en_us&edition=fundamental","pubTime":"2026-04-29 11:22","pubTimestamp":1777432976,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-shares of Mesoblast rise after back-treatment drug hits patent target** Australian shares of Mesoblast MSB.AX rise as much as 4.2% to A$2.24, their biggest intraday pct gain since April 22** Stock among the top gainers in Australia's S&P/ASX 200 index .AXJO, which is down 0.3%** Stock set for a second consecutive session of gains, if current trend holds** The drugmaker says its lower back-treating drug, rexlemestrocel-L, has achieved patient recruitment target** The patent protects the drug from competition, supports higher longterm revenues** Despite moves, MSB down 17.8% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nL6N41C048:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MSB.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631553071","title":"Mesoblast hits recruitment target in Phase 3 chronic low back pain trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2631553071","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631553071?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:53","pubTimestamp":1777424014,"startTime":"0","endTime":"0","summary":"Mesoblast hit recruitment target in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain tied to degenerative disc disease.Top-line results have not been presented yet; readout is expected in mid-CY2027.Study is designed to confirm earlier findings that rexlemestrocel-L reduced pain and supported lower opioid use.Positive results are intended to support an FDA filing in Q3 CY2027, with RMAT status positioning program for priority review once BLA is filed.Mesoblast framed indication as major commercial opportunity, citing potential peak-year revenue above USD 10 billion with single-digit market penetration.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL6PvWb7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","SG9999014013.SGD","BK7067","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","BK4585","IE00B64PRP62.GBP","BK7501","SG9999014005.SGD","LU2210149790.SGD","NDAQ","BK7508","BK4112","LU0314104364.USD","MSB.AU","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014021.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631553020","title":"Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2631553020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631553020?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:53","pubTimestamp":1777423996,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUABQ0Y0N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7508","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629750895","title":"Mesabi Trust (MSB) Q3 Net Margin Strengthens Bearish Dividend Coverage Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2629750895","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629750895?lang=en_us&edition=fundamental","pubTime":"2026-04-24 10:19","pubTimestamp":1776997156,"startTime":"0","endTime":"0","summary":"Mesabi Trust (MSB) has put fresh FY 2026 numbers on the table, with third quarter revenue of US$3.6 million, basic EPS of US$0.21 and net income of US$2.8 million. The trust has seen quarterly revenue move between US$4.7 million and US$6.9 million and EPS range from US$0.28 to US$0.46 over the past year of reported periods, alongside net income between US$3.6 million and US$6.1 million. This sets a clear context for the latest print. With a trailing net margin of 82.8% and earnings quality...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-msb/mesabi-trust/news/mesabi-trust-msb-q3-net-margin-strengthens-bearish-dividend","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-msb/mesabi-trust/news/mesabi-trust-msb-q3-net-margin-strengthens-bearish-dividend","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","MSB.AU","BK7508","BK7067","MSB","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628762489","title":"Mesoblast (ASX:MSB) Is Up 6.1% After FDA Clears Registrational DMD Trial for Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2628762489","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628762489?lang=en_us&edition=fundamental","pubTime":"2026-04-19 21:04","pubTimestamp":1776603864,"startTime":"0","endTime":"0","summary":"On 8 April 2026, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel‑L‑rknd) in 76 children with Duchenne muscular dystrophy, using time‑to‑stand at nine months as the primary endpoint.\nThis marks an expansion of Ryoncil’s use beyond steroid‑refractory acute graft‑versus‑host disease into another rare pediatric indication, leveraging its existing FDA‑approved manufacturing platform and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-61-after-fda-clears-registrational-dm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-61-after-fda-clears-registrational-dm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK7501","BK4588","BK7067","MSB","MSB.AU","LABU","BK4006","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628109572","title":"Mesoblast (ASX:MSB) Valuation Check As New CAR Technology License Targets Stronger Cell Therapy Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2628109572","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628109572?lang=en_us&edition=fundamental","pubTime":"2026-04-16 22:08","pubTimestamp":1776348536,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) recently secured an exclusive worldwide license to a patented chimeric antigen receptor technology from Mayo Clinic, with the goal of refining the targeting and immune effects of its mesenchymal stromal cell therapies.\nSee our latest analysis for Mesoblast.\nAt a share price of A$2.24, Mesoblast has seen a 10.89% 1 month share price return and a 10.34% 7 day share price return. Over 90 days, the share price return is a 15.15% decline, while the 3 year total shareholder...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-new-car-technology-licen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-new-car-technology-licen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4006","BK4230","BK7067","MSB","MSB.AU","BK7501","CAR","BK7508","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627476087","title":"Mesoblast Acquires Exclusive License to Chimeric Antigen Receptor Platform; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627476087","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627476087?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:35","pubTimestamp":1776216917,"startTime":"0","endTime":"0","summary":"Mesoblast  acquired an exclusive license to a patented chimeric antigen receptor technology platform to boost the effectiveness of its products, according to a Wednesday filing with the Australian bourse.The company obtained the rights to the intellectual property developed at Mayo Clinic through the acquisition of a startup mainly formed to advance the technology, the filing said.Shares rose nearly 7% in morning trade Wednesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK4139","MESO","BK7067","BK7501","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627476272","title":"Australian stocks edge higher as investors focus on US-Iran talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2627476272","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627476272?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:30","pubTimestamp":1776216641,"startTime":"0","endTime":"0","summary":"Australian stocks edge higher as investors focus on US-Iran talks April 15 (Reuters) - Australian shares rose for a second straight session on Wednesday, with miners leading the rally, as signs that d","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nL4N40Y012:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBA.AU","BK7508","BK7104","BK7095","BHP.AU","BK7507","NST.AU","BK7501","BK7135","EVN.AU","BK7511","VGN.AU","BK7067","MSB.AU","BK7506","BK7030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627631475","title":"BUZZ-Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech","url":"https://stock-news.laohu8.com/highlight/detail?id=2627631475","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627631475?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:47","pubTimestamp":1776214056,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech** Shares of Mesoblast MSB.AX rise as much as 6% to A$2.13, post their biggest intraday pct gain since March 25** Drug maker acquires exclusive licence to patented chimeric antigen receptor  technology platform ** CAR tech for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell products** Foundational work on the technology was developed by investigators at U.S.-based Mayo Clinic** YTD, MSB down 22.4%  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nL4N40Y01C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","MSB.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627473739","title":"BRIEF-Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2627473739","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627473739?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:34","pubTimestamp":1776213242,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Acquires CAR Platform For Precision-Enhanced Cell ProductsApril 15  - Mesoblast Ltd MSB.AX:MESOBLAST LTD-ACQUIRES CAR PLATFORM FOR PRECISION-ENHANCED CELL PRODUCTSACQUIRES CAR PLATFORM FOR PRECISION-ENHANCED CELL PRODUCTS-MSB.AXTO INCORPORATE ENGINEERED CARS TO ENHANCE PRODUCT SPECIFICITYOBTAINS WORLDWIDE EXCLUSIVE RIGHTS TO CAR-MSC IP FROM MAYO CLINICMAYO CLINIC TO PROVIDE IN-KIND SUPPORT AND GMP MANUFACTURING FOR CAR-MSC TECHNOLOGYFurther company coverage: MSB.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUE6S1NMB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","BK7501","BK7508","MSB.AU","BK7067","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120433271","title":"Stock Track | Mesoblast Soars 5.22% Intraday on Acquisition of CAR-MSC Platform with Exclusive Mayo Clinic License","url":"https://stock-news.laohu8.com/highlight/detail?id=1120433271","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120433271?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:18","pubTimestamp":1776212319,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock surged 5.22% during intraday trading on Wednesday, following a series of announcements regarding a significant strategic acquisition.The company acquired a startup holding an...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627478039","title":"Mesoblast acquires CAR-MSC platform startup, secures exclusive Mayo Clinic license","url":"https://stock-news.laohu8.com/highlight/detail?id=2627478039","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627478039?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:11","pubTimestamp":1776211877,"startTime":"0","endTime":"0","summary":"Mesoblast acquired a startup holding an exclusive worldwide license to patented CAR technology for genetically engineered mesenchymal stromal cell  products.Platform, developed at Mayo Clinic, is intended to improve MSC targeting to inflamed tissue to boost potency in inflammatory diseases.Near-term development focus includes CAR-MSC candidates for ulcerative colitis or Crohn’s disease.Mesoblast also plans CAR-MSC engineered to express CD19 for lupus nephritis and other B-cell autoimmune diseases.Consideration was paid via issuance of ASX ordinary shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL9tRQgt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210149790.SGD","MSB.AU","BK7501","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","SG9999014021.USD","IE00BN0W2T93.GBP","NDAQ","SG9999014039.USD","IE00BN0W2W23.USD","LU2210150020.SGD","BK7067","BK4588","BK4112","LU2095319765.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","SG9999014005.SGD","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627787174","title":"Mesoblast Acquires Chimeric Antigen Receptor (Car) Platform Technology for Precision-Enhanced Cell Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2627787174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627787174?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:10","pubTimestamp":1776211856,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA4VW602:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627442075","title":"Mesoblast Ltd-Acquires Car Platform for Precision-Enhanced Cell Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2627442075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627442075?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:25","pubTimestamp":1776209153,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUE6S1NMB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","MSB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627420766","title":"Mesoblast Ltd - Obtains Worldwide Exclusive Rights to Car-MSC Ip From Mayo Clinic","url":"https://stock-news.laohu8.com/highlight/detail?id=2627420766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627420766?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:25","pubTimestamp":1776209153,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUE6S1NMB:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK7067","MSB.AU","MESO","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627207504","title":"Mesoblast Ltd - to Incorporate Engineered Cars to Enhance Product Specificity","url":"https://stock-news.laohu8.com/highlight/detail?id=2627207504","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627207504?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:25","pubTimestamp":1776209153,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUE6S1NMB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MESO","MSB.AU","BK7508","BK7067","BK4139","BK7501"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":8,"totalSize":164,"code":"91000000","status":"200"}]}}